Sarcopenia - Pipeline Insights, 2022

DelveInsight's , "Sarcopenia - Pipeline Insight, 2021," report provides comprehensive insights about 12+ companies and 14+ pipeline drugs in Sarcopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Sarcopenia Understanding

Sarcopenia: Overview

Sarcopenia is a musculoskeletal disease in which muscle mass, strength, and performance are significantly compromised with age. Sarcopenia most commonly affects elderly and sedentary populations and patients who have comorbidities that affect the musculoskeletal system or impair physical activity. The diagnosis of sarcopenia encompasses decreased levels of the following 3 traits: muscle strength, muscle quantity or quality, and physical performance. Causes of sarcopenia are generally attributable to the natural processes of aging, which are not entirely understood and are multifaceted. Risk factors for sarcopenia include age, gender and level of physical activity. The main treatment path for sarcopenia is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to people with sarcopenia. HRT can help to raise lean body mass, decrease abdominal fat, and prevent bone deterioration in women whose hormone levels decrease with menopause. However, the use of HRT is debated because of an increased risk of some cancers and other severe health conditions. Some other treatments that are under investigation include: growth hormone supplements, testosterone supplements, hydroxy methylbutyrate, angiotensin converting enzyme inhibitors, vitamin D, and medications for the treatment of metabolic syndromes.

"Sarcopenia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sarcopenia pipeline landscape is provided which includes the disease overview and Sarcopenia treatment guidelines. The assessment part of the report embraces, in depth Sarcopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence Sarcopenia R&D. The therapies under development are focused on novel approaches to treat/improve Sarcopenia.

Sarcopenia Emerging Drugs Chapters

This segment of the Sarcopenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sarcopenia Emerging Drugs

Sarconeos (BIO101): Biophytis

Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity in various age-related and muscular wasting conditions. Preclinical studies have demonstrated that Sarconeos (BIO101) activates the MAS receptor in muscle cells, a key component of the Renin-Angiotensin System (RAS). The RAS is a fundamental endocrine system that is known to control fluid balance, blood pressure and cardio-vascular function. The RAS is also involved in the regulation of smooth, cardiac and skeletal muscle metabolism and plays a key role in muscle function and mobility in disease states. Biophytis has reported topline results of SARA-INT Phase II Study with Sarconeos (BIO101) in Sarcopenia. Sarconeos (BIO101) has the potential to be the first drug candidate to enter Phase III in sarcopenia. Following discussions with regulatory authorities in Europe and the United States, the goal is to obtain all regulatory approvals in the second half of 2022 in order to be able to initiate the Phase III clinical trial.

MYMD-1: MyMD Pharmaceuticals

Originally developed for autoimmune diseases, MYMD-1's primary purpose is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan. Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. MYMD-1 is also showing promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.

In January 2022, MyMD Pharma announced that he U.S. Patent and Trademark Office (USPTO) awarded to the company U.S. Patent 11,219,620 B2, titled "Method of Treating Sarcopenia." The patent was issued on January 11, 2022. Currently it is being evaluated in Phase II clinical studies to treat patients with Sarcopenia.

Further product details are provided in the report……..

Sarcopenia: Therapeutic Assessment

This segment of the report provides insights about the different Sarcopenia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Sarcopenia

There are approx. 12+ key companies which are developing the therapies for Sarcopenia. The companies which have their Sarcopenia drug candidates in the most advanced stage, i.e. phase III include, Biophytis.

Phases

DelveInsight's report covers around 14+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as:

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sarcopenia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sarcopenia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sarcopenia drugs.

Sarcopenia Report Insights

• Sarcopenia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sarcopenia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Sarcopenia drugs?

• How many Sarcopenia drugs are developed by each company?

• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sarcopenia?

• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sarcopenia therapeutics?

• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

• What are the clinical studies going on for Sarcopenia and their status?

• What are the key designations that have been granted to the emerging drugs?

Key Players

• Lipocine Inc.
• MyMD Pharmaceuticals
• Biophytis
• Dystrogen Therapeutics
• Oncocross Therapeutics
• OPKO health
• NMD Pharma
• Rejuvenate Biomed
• Immunoforge
• Rubedo Life Sciences
• Faraday Pharmaceuticals

Key Products

• LPCN 1148
• MYMD-1
• BIO10
• AXA1665
• DT-201
• OC514
• OPK88004
• NMDP-05
• RJx-01
• PF1801